Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLP2117 and QL2107 in Advanced Solid Tumors
NCT06911827Phase 2Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PSB114 in solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-limiting toxicity at 21 days, Percentage of Participants Experiencing Adverse Events at 96 weeks and 1 more. Started May 2025; status: recruiting.
02
Drugs
PSB114
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06911827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911827.